Aldesleukin
- Generic Name
- Aldesleukin
- Brand Names
- Proleukin
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 110942-02-4
- Unique Ingredient Identifier
- M89N0Q7EQR
- Background
Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125.
- Indication
For treatment of adults with metastatic renal cell carcinoma.
- Associated Conditions
- Metastatic Melanoma, Metastatic Renal Cell Carcinoma ( mRCC)
- Associated Therapies
- -
T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers
- Conditions
- Cervical CancerAnal CancerOropharyngeal CancerVaginal CancerPenile Cancer
- Interventions
- First Posted Date
- 2014-11-02
- Last Posted Date
- 2017-09-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 12
- Registration Number
- NCT02280811
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive
- Conditions
- Cervical CancerMelanomaBreast CancerBladder CancerRenal Cancer
- Interventions
- Drug: AldesleukinDrug: FludarabineDrug: CyclophosphamideBiological: Anti-MAGE-A3 human leukocyte antigen serotype within HLA-A A serotype group (HLA-A* 01)-restricted T-cell receptor (TCR)
- First Posted Date
- 2014-06-03
- Last Posted Date
- 2019-06-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 3
- Registration Number
- NCT02153905
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
- Conditions
- Advanced Non-Small Cell Lung CancerAdvanced NSCLCSquamous Cell CarcinomaAdenosquamous CarcinomaAdenocarcinoma
- Interventions
- First Posted Date
- 2014-05-07
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 85
- Registration Number
- NCT02133196
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive
- Conditions
- MelanomaCervical CancerBreast CancerRenal CancerUrothelial Cancer
- Interventions
- Biological: Anti-MAGE-A3-DP4 T Cell Receptor (TCR) Peripheral Blood Lymphocytes (PBL)Drug: CyclophosphamideDrug: FludarabineDrug: Aldesleukin
- First Posted Date
- 2014-04-11
- Last Posted Date
- 2022-03-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 21
- Registration Number
- NCT02111850
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
- Conditions
- Skin CancerMelanoma
- Interventions
- Drug: AldesleukinDrug: FludarabineDrug: CyclophosphamideBiological: 4-1BB Selected Tumor Infiltrating Lymphocytes (TIL)
- First Posted Date
- 2014-04-11
- Last Posted Date
- 2017-09-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 6
- Registration Number
- NCT02111863
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma
- Conditions
- Metastatic CancerMetastatic Melanoma
- Interventions
- Biological: Anti-NY ESO-1 T cell receptor (TCR) cluster of differentiation 62L (CD62L)+ cellsDrug: AldesleukinDrug: CyclophosphamideDrug: Fludarabine
- First Posted Date
- 2014-02-13
- Last Posted Date
- 2016-06-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 2
- Registration Number
- NCT02062359
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
- Conditions
- Metastatic Melanoma
- Interventions
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2023-01-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 33
- Registration Number
- NCT01993719
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
- Conditions
- Breast CancerMeningiomaNon-Small Cell Lung CancerMelanomaHepatocellular Cancer
- Interventions
- First Posted Date
- 2013-10-23
- Last Posted Date
- 2021-03-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 11
- Registration Number
- NCT01967823
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma
- Conditions
- Metastatic MelanomaStage III Cutaneous Melanoma AJCC v7Stage IIIA Cutaneous Melanoma AJCC v7Stage IIIB Cutaneous Melanoma AJCC v7Stage IIIC Cutaneous Melanoma AJCC v7Stage IV Cutaneous Melanoma AJCC v6 and v7
- Interventions
- Biological: AldesleukinDrug: CyclophosphamideDrug: Fludarabine PhosphateOther: Laboratory Biomarker AnalysisBiological: NGFR-transduced Autologous T LymphocytesBiological: TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes
- First Posted Date
- 2013-10-07
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 34
- Registration Number
- NCT01955460
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma
- Conditions
- Metastatic Ocular MelanomaMetastatic Uveal Melanoma
- Interventions
- Drug: AldesleukinDrug: CyclophosphamideDrug: FludarabineBiological: Young Tumor Infiltrating Lymphocytes (TIL)
- First Posted Date
- 2013-03-19
- Last Posted Date
- 2018-10-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT01814046
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.